Certara Launches Cardiac Safety Simulator V2.0

April 2, 2015
Applied Clinical Trials Editorial Staff

Applied Clinical Trials

Certara®, a global biosimulation technology-enabled consultancy, announced version 2.0 of its Cardiac Safety Simulator (CSS), which has become a standalone product for the first time. CSS is an alternative to Thorough QT/QTc (TQT) studies.

Certara®, a global biosimulation technology-enabled consultancy, announced version 2.0 of its Cardiac Safety Simulator (CSS), which has become a standalone product for the first time. CSS is an alternative to Thorough QT/QTc (TQT) studies. CSS uses drug-triggered cardiac ion-current disruption data, together with predicted in-vivo exposure information to evaluate the factors influencing potential cardiac risk.

CSS v2.0 offers new features including the following:

  • Enhanced QSAR models for predicting drug-triggered IKr, IKs, INa and ICaL current inhibition based on automatically-calculated phys-chem data (when in-vitro data are not available)

  • Predicts population variability and drug-triggered physiology modifications

  • Permits assessment of the potential impact of disease and genotypes; allows for genotype-related ionic current modification at the multiple channels level

  • Contains an additional human left ventricular muscle cell model

  • Evaluates up to seven chemical species (drugs, metabolites and other substances) simultaneously that are interacting at the ion channel(s) level

  • Provides a new flexible, Excel-based tool to enhancevisualization and analysis of simulation results

 

 

Read the full release.

Related Content:

News